RANKL-blockade for the Treatment of Erosive Osteoarthritis (OA) of Interphalangeal Finger Joints
Study Details
Study Description
Brief Summary
This is a randomized, double blind placebo controlled one-site proof-of-concept study in subjects with erosive osteoarthritis (OA) of interphalangeal (IP) finger joints.
A total of 100 subjects will be enrolled into the study: 48 weeks placebo controlled double-blind phase with denosumab 60mg every 12 weeks, followed by a 48-week open-label phase in which all subjects will receive denosumab.
| Condition or Disease | Intervention/Treatment | Phase |
|---|---|---|
|
Phase 2 |
Detailed Description
Investigational therapy: denosumab 60mg subcutaneous injection every 12 weeks. All subjects will receive Calcium/vit D supplementation.
Efficacy objectives:
The primary objective is to assess the effect of denosumab on the reduction of radiographic erosive progression using GUSS (Ghent University Score System).
The secondary objective is to assess the effect of denosumab on the reduction of radiographic erosive progression as defined by diminishing the appearance of new erosive IP finger joints.
The exploratory objective is mainly to assess the effect of denosumab on clinical variables, as well as ultrasonography and DEXA (dual energy x-ray absorptiometry) parameters.
Study Design
Arms and Interventions
| Arm | Intervention/Treatment |
|---|---|
| Active Comparator: Experimental: denosumab 50 patients will be enrolled in this group for a total treatment duration of 24 months (96 weeks): 48 weeks denosumab 60mg sc every 12 weeks followed by a 48-weeks open label phase denosumab 60mg sc every 12 weeks. Calcium and vit D supplementation will be installed at baseline. |
Drug: denosumab
60mg sc
Other Names:
Dietary Supplement: Calcium/Vit D supplementation
Daily dosage Calcium 1000mg / Vit D 880 IU
Other Names:
|
| Placebo Comparator: Comparator 50 patients will be enrolled in this group for a total treatment duration of 24 months (96 weeks): 48 weeks placebo sc every 12 weeks followed by a 48-weeks open label phase denosumab 60mg sc every 12 weeks. Calcium and vit D supplementation will be installed at baseline |
Drug: denosumab
60mg sc
Other Names:
Drug: Placebo
identical syringe
Other Names:
Dietary Supplement: Calcium/Vit D supplementation
Daily dosage Calcium 1000mg / Vit D 880 IU
Other Names:
|
Outcome Measures
Primary Outcome Measures
- Evaluate the change in the negative evolution in GUSS scores in the target IP joints from baseline to week 24 [24 weeks]
A quantitative radiographic scoring system, the Ghent University Scoring System, GUSS, is a reliable method to score radiographic change over time in erosive IP OA and detects more progression over a shorter period of time than scored by indicating the proportions of normal subchondral bone, subchondral plate and joint space over time.
Other Outcome Measures
- Evaluate the change in the negative evolution in GUSS scores in the target IP joints from week 24 to week 48 and from baseline to week 48 [48 weeks]
- Evaluate a reduction in radiographic erosive progression as defined by diminishing the appearance of new erosive IP finger joints. [48 weeks]
This will be assessed by the number of patients that develop new erosive IP joints ('S/J' to 'E' joints) at 48 weeks.
- Evaluate a reduction in radiographic erosive progression as defined by diminishing the appearance of new erosive IP finger joints. [48 weeks]
This will be assessed by the number of 'S/J' IP joints that develop 'E' phases at 48 weeks.
- To assess if denosumab provides clinical benefits (improvement of pain and functional limitations) compared to placebo. [48 weeks]
The impact on ultrasonography and DEXA will be evaluated. Changes in clinical and patient recorded outcome measures from baseline (day 1) to week 48 after administration of denosumab compared to placebo.
- To assess if denosumab provides clinical benefits (improvement of pain and functional limitations) compared to placebo. [12 weeks]
The impact on ultrasonography and DEXA will be evaluated: Changes in sonographic inflammatory signals from baseline at week 12. Inflammatory changes will be assessed by measuring the amount of effusion and Power Doppler signal.
- To assess if denosumab provides clinical benefits (improvement of pain and functional limitations) compared to placebo. [48 weeks]
The impact on ultrasonography and DEXA will be evaluated: Changes in sonographic inflammatory signals from baseline at week 48. Inflammatory changes will be assessed by measuring the amount of effusion and Power Doppler signal.
- To assess if denosumab provides clinical benefits (improvement of pain and functional limitations) compared to placebo. [48 weeks]
The impact on ultrasonography and DEXA will be evaluated. Effect of denosumab on bone mass densitometry score in this group of patients compared to placebo from baseline to week 48.
- Assess the safety profile of the administration of denosumab 60mg every 3 months in the population of patients with erosive OA. [48 weeks]
Number of patients who have experienced (S)AE.
Eligibility Criteria
Criteria
Inclusion Criteria:
-
• Subjects with hand OA having suffered from transient inflammatory attacks of the interphalangeal finger joints characteristic for what has been termed 'inflammatory' or 'erosive' hand OA.
-
Subjects with hand OA showing inflammatory signs, either clinically or ultrasonographically, of the interphalangeal finger joints.
-
Subjects with hand OA in which at least 1 interphalangeal finger joint has the typical appearance on the X-rays of a 'J' or 'E' phase joint as defined by the criteria mentioned above.
-
Subjects with hand OA where at least 1 interphalangeal finger joint in the 'J' or 'E' phase presents a palpable swelling.
Exclusion Criteria:
-
• Patients with known hypersensitivities to mammalian-derived drug preparations.
-
Patients with clinically significant hypersensitivity to any of the components of Prolia.
-
Current and/or Prior treatment with any investigational agent within 90 days, or five half-lives of the product, whichever is longer.
-
Previous administration of denosumab from clinical trials or others (e.g. commercial use).
-
Vitamin D deficiency [25(OH) vitamin D level < 20 ng/mL (< 49.9 nmol/L)]. Possibility of replenishment and re-screening.
-
Subjects with current hypo- or hypercalcemia (normal serum calcium levels: 8.5-10.5 mg/dl or 2.12-2.62 mmol/L).
-
Patients currently under bisphosphonate (BP) treatment or any use of oral BPs within 12 months of study enrollment or intravenous BPs or strontium ranelate within 5 years of study enrollment
-
Prior use of any chondroprotective drug within 90 days e.g. chondroitin sulfate, glucosamine, avocado-soybean unsaponifiables, tetracyclins, corticosteroids.
-
Prior use of any immunomodulating drug with possible effects on proinflammatory cytokine metabolism within 90 days a.o. corticosteroids, methotrexate, sulfasalazine, leflunomide, D-Penicillin, anti-malarials, cytotoxic drugs, TNF (tumor necrosis factor) blocking agents.
-
History of drug or alcohol abuse in the last year.
-
Patients suffering from chronic inflammatory rheumatic disease (e.g. rheumatoid arthritis, spondylarthropathy, psoriatic arthritis, gout, chondrocalcinosis or other auto-immune diseases, e.g. systemic lupus erythematosus).
-
History of cancer or lymphoproliferative disease other than a successfully and completely treated squamous cell or basal cell carcinoma of the skin or cervical dysplasia, with no recurrence within the last two years.
-
History of any Solid Organ or Bone Marrow Transplant.
-
Comorbidities: significant renal function impairment (glomerular filtration < 30 ml/min/1.73m2 or <50% of normal value), uncontrolled diabetes, unstable ischemic heart disease, congestive heart failure (NYHA III, IV), uncontrolled hypo or hyperparathyroidism, active inflammatory bowel disease, malabsorption, liver failure or chronic hepatic disease (serum AST (aspartate aminotransferase )/ ALT (alanine aminotransferase) levels 3 times above normal), recent stroke (within three months), chronic leg ulcer and any other condition (e.g,. indwelling urinary catheter) which, in the opinion of the investigator, would put the subject at risk by participation in the protocol.
-
Subject has any kind of disorder that compromises the ability of the subject to give written informed consent and/or to comply with study procedures .
-
Patient who is pregnant or planning pregnancy; if the female subject is of child-bearing age, she must use a valid mean of contraception during the study and for 9 months after last dose of study medication. For males with a partner of childbearing potential: subject refuses to use 1 effective methods of contraception for the duration of the study and for 10 months after the last dose of study medication.
-
Female subjects who are breast-feeding.
-
History of osteonecrosis of the jaw, and/or recent (within 3 months) tooth extraction or other unhealed dental surgery; or planned invasive dental work during the study.
Contacts and Locations
Locations
| Site | City | State | Country | Postal Code | |
|---|---|---|---|---|---|
| 1 | UZ Ghent | Gent | Belgium | 9000 |
Sponsors and Collaborators
- University Hospital, Ghent
- Amgen
Investigators
- Principal Investigator: Dirk Elewaut, Prof. Dr., UZ Ghent
- Principal Investigator: August Verbruggen, Prof Dr. Em., UZ Ghent
Study Documents (Full-Text)
None provided.More Information
Publications
None provided.- AGO/2015/008
- 2015-003223-53